Demonstrating the Role of Intermediate Clinical Endpoints for Cancer of the Prostate (ICECaP) in Estimating Economic Value”

Project Member(s): De Abreu Lourenco, R.

Funding or Partner Organisation: New Organisation (New Fund Source)
ANZUP Cancer Trials Group Ltd (ANZUP Clincal Trials Group Ltd)

Start year: 2017

Publications:

Xie, W, Regan, MM, Buyse, M, Halabi, S, Kantoff, PW, Sartor, O, Soule, H, Berry, D, Clarke, N, Collette, L, D’Amico, A, Lourenco, RDA, Dignam, J, Eisenberger, M, James, N, Fizazi, K, Gillessen, S, Loriot, Y, Mottet, N, Parulekar, W, Sandler, H, Spratt, DE, Sydes, MR, Tombal, B, Williams, S & Sweeney, CJ 2020, 'Event-Free Survival, a Prostate-Specific Antigen–Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation', Journal of Clinical Oncology, vol. 38, no. 26, pp. 3032-3041.
View/Download from: Publisher's site

Sweeney, CJ, De Abreu Lourenco, R, Hamid, AA & Buyse, M 2019, 'What Does Metastasis-Free Survival Actually Mean?', Journal of Clinical Oncology, vol. 37, no. 19, pp. 1679-1680.
View/Download from: Publisher's site

De Abreu Lourenco, R & Williams, SG 2018, 'Building an Understanding of the Value of Docetaxel Plus Hormone Therapy in Prostate Cancer: An Ever-growing Evidence Base', European Urology Oncology, vol. 1, no. 6, pp. 459-460.
View/Download from: Publisher's site

De Abreu Lourenco, R 1970, 'Does one size fit all? Determining value of prostate cancer and urology care', ANZUP Annual Scientific Meeting, Melbourne.

FOR Codes: Health Economics, Evaluation of Health Outcomes, Health Policy Economic Outcomes, Health economics , Health policy evaluation, Evaluation of health and support services not elsewhere classified